NCT03368729: Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

NCT03368729
Breast Cancer Type: HER2+
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known active central nervous system (CNS) metastases; Known germline BRCA 1/2 mutations
https://ClinicalTrials.gov/show/NCT03368729

Comments are closed.

Up ↑